18257results about "Unknown materials" patented technology

The present invention provides substituted tricyclic compound of formula (I), which are therapeutically useful as KRAS degraders. These compounds are useful in the treatment and / or prevention of diseases or disorders dependent upon KRAS. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof thereof.

Provided herein are compounds of Formula (I), or a pharmaceutically acceptable form thereof, and pharmaceutical compositions comprising the same. Also provided herein methods of modulating the activity of cellular targets by administering to a subject a compound of Formula (I), or a pharmaceutically acceptable form thereof. Further provided herein are methods of treating cancer, fibrotic diseases, and inflammatory diseases by administering to a subject a compound of or a pharmaceutically acceptable form thereof.

The present invention particularly relates to a Lactiplantibacillus plantarum strain having a weight-reducing function, a live bacterium formulation, a preparation method therefor, and the use thereof. The Lactiplantibacillus plantarum strain is preserved in China General Microbiological Culture Collection Center (CGMCC) of China Committee for Culture Collection of Microorganisms, the accession number thereof being CGMCC No. 25683. The Lactiplantibacillus plantarum strain and the live bacterium formulation thereof can inhibit the growth of an obesity bacterial strain Enterobacter cloacae, reduce the cholesterol, and inhibit the differentiation of 3T3-L1 preadipocytes, so as to reduce the body weight of an obesity model mouse and reduce the total weight gain and total food utilization rate of an obesity model rat, thereby achieving an excellent weight-reducing function.

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.

The invention discloses lactobacillus kefiranofaciens IMAU12319 and application thereof, belongs to the technical field of microorganisms, and particularly relates to lactobacillus kefiranofaciens IMAU12319 which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 8, 2024, the preservation address is No. 3, No.1 yard, West Beichen Road, Chaoyang District, Beijing, and the number is CGMCC No.31224. The lactobacillus kefiranofaciens IMAU12319 has the advantages that the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319, and the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319; the invention also relates to an application of the lactobacillus kefiranofaciens IMAU12319 in preparation of a probiotic agent capable of resisting gastrointestinal digestion. The strain disclosed by the invention not only shows good gastrointestinal tract endurance capacity, but also shows relatively strong potential in the aspects of intestinal adhesion, oxidation resistance and bacteriostasis, and has a wide application prospect in leavening agent strains.

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention provides a plant lactobacillus capable of promoting mineral absorption and transport and application of the plant lactobacillus. The invention provides a plant lactobacillus of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.32404. The invention also provides a culture, a sterilized solution, a supernatant, a filtrate, a diluent, a precipitate or freeze-dried powder, a composition and a probiotic preparation containing the plant lactobacillus, and related applications and methods thereof.

The disclosure provides Bifidobacterium longum subsp. infantis CCFM1269 and an application thereof, and belongs to the technical field of microorganisms. The B. longum subsp. infantis CCFM1269 provided by the disclosure is a food safety strain, which has the effects of regulating the Th1 / Th2 balance and the IgA content of a mammal in an early life stage, enhancing the skeletal development, improving the femur length and skeletal steady state in the early life stage and the like, and thus the strain has a huge application prospect. Only a culture medium and control of some culture conditions are needed in a culture process of the strain, so that the cost is relatively low, and industrial production is easily implemented.

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention relates to the technical field of microorganisms, and in particular relates to application of a strain of lactobacillus mucus TG018. The invention further relates to a preparation method of the lactobacillus mucus TG018. The preservation number of the lactobacillus mucus TG018 is CCTCC (China Center for Type Culture Collection) No: M 2023514; the lactobacillus mucus TG018 can be used for producing nicotinic acid, serving as an antioxidant and / or preparing the antioxidant, or can be applied to medicines for reducing uric acid.

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The pediococcus acidilactici SWU-HX39 with the uricemia reducing function is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33055, the preservation date is December 13, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici SWU-HX39 disclosed by the invention can be used for relieving kidney injury caused by hyperuricemia; synthesis of uric acid can be reduced, the concentration of uric acid in blood can be reduced, the excretion capacity of the body to the uric acid is improved, reabsorption of the body to the uric acid is reduced, and the effect of reducing the uric acid is achieved through two ways; in addition, the SWU-HX39 can be used for reducing the expression of LPS (Lipopolysaccharide), and reducing the expression of inflammatory factors IL-1beta, IL-6 and TNF (Tumor Necrosis Factor) alpha at the same time. The traditional Chinese medicine composition not only has the effects of resisting inflammation and relieving liver inflammation, but also can improve the SCFAs content, especially propionic acid, in the body of a hyperuricemia patient, so that the uric acid level is reduced, and the abnormal uric acid content is improved.

The invention provides an application of a fermentation lactobacillus mucus strain A21196 in preparation of a product for resisting anxiety and improving memory and concentration, and belongs to the technical field of biological medicines. Animal experiments show that the fermented lactobacillus mucus strain A21196 has the effects of resisting anxiety, resisting depression, improving cognitive impairment function and improving memory concentration, and provides a new means for preventing and / or treating nerve diseases related to anxiety disorder, depression and cognitive impairment.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum with an antibacterial effect and application of the lactobacillus plantarum, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) No.33151. The strain provided by the invention has relatively strong cholate resistance, gastric acid resistance, acid production and H2O2 production capabilities, and has a relatively strong bacteriostatic effect on common pathogenic bacteria such as staphylococcus aureus, candida albicans, escherichia coli, salmonella and helicobacter pylori; the compound can inhibit the activity of urease, interfere helicobacter pylori colonization and the like to inhibit helicobacter pylori infection or reduce the symptoms of helicobacter pylori infection and reduce the disease degree of mice with colitis, can be used for preparing microbial preparations, and has the potential of preparing drugs for preventing and / or treating diseases caused by helicobacter pylori infection.

The invention relates to the field of microorganisms, in particular to a plant lactobacillus and application thereof in bacteriostasis. Specifically, the preservation number of the plant lactobacillus LP06 is CGMCC (China General Microbiological Culture Collection Center) No. 28412. The plant lactobacillus LP06 provided by the invention can be used for inhibiting the growth of debaryomyces hansenii, candida tropicalis and penicillium rochei, and also has an inhibiting effect on super bacteria acinetobacter baumannii, pseudomonas aeruginosa, klebsiella, escherichia coli, staphylococcus aureus and listeria monocytogenes. The plant lactobacillus LP06 provided by the invention has broad-spectrum bacteriostatic ability, and bacteriostatic powder prepared from the bacterium can be used as a biological preservative for corrosion prevention of dairy products such as yoghourt, cheese and the like and other foods.

The invention discloses a probiotic with the depression improving effect and a microecological preparation and application thereof, and is characterized in that the probiotic comprises lactobacillus mucus PC17 with the preservation number of CGMCC No.33866, the active ingredients of the lactobacillus microecological preparation comprise thalli of the lactobacillus mucus PC17, and a preparation method of the microecological preparation comprises the following steps: adding the lactobacillus mucus PC17 into the lactobacillus mucus PC17, uniformly mixing the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17, the lactobacillus mucus PC17 and the lactobacillus mucus PC17 The lactic acid bacteria are inoculated into a fermentation culture medium according to a volume ratio of 1-5% to prepare the lactic acid bacteria microecological preparation, can be used for preparing antidepressant drugs, and has the advantages of being capable of promoting RIN14B cells to secrete 5-hydroxytryptamine and 5-hydroxytryptophan, reducing the levels of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, corticosterone and corticotropin in serum, and improving the antidepressant activity of the antidepressant drugs. The levels of aminobutyric acid and brain-derived neurotrophic factors in serum are improved, and the depression-like behaviors of CUMS depression model mice are obviously improved.

The invention provides a Lactobacillus paracasei, which has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The Lactobacillus paracasei has a preservation number of CGMCC No.32951. The lactobacillus paracasei ID001 provided by the invention has an inhibition effect on enteropathogenic bacteria such as salmonella, escherichia coli, staphylococcus aureus and the like. The probiotic preparation is obtained through fermentation and the dendrobium officinale extract, and the probiotic preparation has the immunoregulation effect through performance verification and screening.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention relates to the field of microorganisms, and discloses lactobacillus plantarum and application of the lactobacillus plantarum in preparation of a medicine for preventing and / or treating vaginitis, and the preservation number of the lactobacillus plantarum is CGMCC No.33152. The lactobacillus plantarum provided by the invention has a relatively strong bacteriostatic effect on common vaginal pathogenic bacteria such as Atortoria, staphylococcus aureus, Candida albicans, Escherichia coli and Gardneria, and also can reduce the infection degree of the pathogenic bacteria by inhibiting colonization and reproduction of the pathogenic bacteria; in addition, the proinflammatory factor level in sick vaginitis tissues is reduced, and the anti-inflammatory factor level is improved.

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The invention relates to the technical field of microorganisms, in particular to a viable bacterium preparation of a lactobacillus paracasei strain as well as a preparation method and application of the viable bacterium preparation. The viable bacterium preparation comprises a lactobacillus paracasei strain and auxiliary materials, and the preservation number of the lactobacillus paracasei strain is CGMCC (China General Microbiological Culture Collection Center) No.27974. The viable bacterium preparation can inhibit the growth of streptococcus mutans, reduce the formation of a dental plaque biofilm caused by the streptococcus mutans, reduce the content of a mature dental plaque biofilm, inhibit the level of water-insoluble exopolysaccharides generated by the streptococcus mutans, reduce the expression quantity of cariogenic genes gtfB, gtfC, gtfD, ftf and LuxS of the streptococcus mutans, improve the cariogenic activity of the streptococcus mutans and improve the cariogenic activity of the streptococcus mutans. The adhesion rate of streptococcus mutans on a hydroxyapatite tooth model is reduced, and a beneficial in-vitro probiotic function is achieved.

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

The invention discloses lactococcus gasseri C6a2 and application thereof. The preservation number of the lactococcus gasseri C6a2 is CGMCC (China General Microbiological Culture Collection Center) NO: 31024; the 16S rRNA (ribosomal Ribonucleic Acid) gene sequence of the lactococcus gasseri C6a2 is as shown in SEQ ID NO: 1. The bacterial strain is a macrobrachium rosenbergii intestinal absolute dominant bacterium, has a typical probiotic function, is high in growth speed and activity, can quickly enter a logarithmic phase, has relatively high acid production and acid resistance, can secrete lipase, has relatively high bacteriostatic activity on staphylococcus aureus, aeromonas hydrophila and aeromonas veronii, and can be used for preparing the macrobrachium rosenbergii. The bacterium can be used for preparing a special probiotic preparation for macrobrachium rosenbergii, so that the sustainable development of the macrobrachium rosenbergii industry in China is promoted.

The invention provides a traditional Chinese medicine composition and an application thereof in preparing a product for preventing, alleviating or treating acute hepatopancreatic necrosis of shrimp, belonging to the field of veterinary medicine. The active ingredients of the traditional Chinese medicine composition include isatis root, artificial bezoar, liquorice, borneol, pig gall powder and xuanming powder. The traditional Chinese medicine composition has a good therapeutic effect on preventing, alleviating or treating acute hepatopancreatic necrosis of shrimp, with a cure rate of more than 70%, has antibacterial and liver-protecting effects, can effectively improve the degree of liver damage, improve the survival rate of shrimp and reduce losses.

The invention relates to Pediococcus pentosaceus PP90 for preventing and treating alcoholic nerve injury and application of the Pediococcus pentosaceus PP90, the Pediococcus pentosaceus PP90 is preserved in China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.32034. The Pediococcus pentosaceus PP90 can be used for preventing and treating alcoholic nerve injury. The fermentation product of the pediococcus pentosaceus PP90 can degrade the alcoholic strength of alcohol, can generate ethanol dehydrogenase and acetaldehyde dehydrogenase, can improve the activity of nerve cells, can regulate the expression of cytokines, can inhibit the activation of astrocytes, can regulate the expression of brain-derived neurotrophic factors, and can inhibit the growth of the brain-derived neurotrophic factors. The compound can improve the disordered neurotransmitter level, and can be used for preparing products for preventing or improving alcoholic nerve injury.

Building on U.S. Provisional Patent Application No. 63 / 693,803, paragraphs for 2D-to-3D conversion and [0023]-[0024] for secure content verification, the Matrix 3D AI Polygon Mesh Hash Key System revolutionizes transforming 2D content into secure, interactive 3D AR / VR assets. Integrating AI and LiDAR, it enables real-time 3D mesh generation with precise geospatial anchoring. Users can reshape 3D content instantly via natural language commands, enhancing interactivity. Quantum-resistant encryption, using AES-256 and CRYSTALS-Kyber, ensures robust asset security. The system excels in gaming, surveillance, content verification, military operations, space exploration, deepfake detection, and pharmaceutical research, offering unmatched precision and scalability. Its multi-stage rendering pipeline, powered by distributed AI-driven bots, supports efficient real-time 3D mesh generation, achieving 95% accuracy and 1 cm resolution. This AR / VR technology advancement transforms industries with scalable, secure solutions for interactive 3D content creation and management, setting a new standard for precision and versatility.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention relates to the technical field of microorganisms, and provides lactobacillus mucilaginosus for maintaining genital tract health and preventing genital tract infection and application of lactobacillus mucilaginosus. Fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection is named as FMTA1113H and is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.34291. The invention further discloses a preparation method of the fermented mucus lactobacillus for maintaining genital tract health and preventing genital tract infection. According to the technical scheme, the problems that female genital tracts are prone to infection and relapse is prone to occurring after infection in the prior art are solved.